GSK plc (NYSE: GSK) — Recovery Priced, Cliff Unsolved: The Cheapest Big-Pharma Quality, Discounted for Two Good Reasons

Independent equity research · Report date: 2026-07-03 · Fresh coverage

Reporting note: GSK plc is a UK-domiciled foreign private issuer reporting under IFRS in GBP; it files Form 20-F (annual) and 6-K (interim) rather than 10-K/10-Q, and pays no US-style DEF 14A proxy (director dealings appear as RNS “PDMR” notices). It lists on the NYSE via an ADR: one ADS = two ordinary shares (~4.01bn ordinary shares → ~2.006bn ADRs). Confirm by arithmetic: ~$53.66 ADR × ~2.006bn ≈ ~$108bn market cap ≈ ~£83bn. All per-share figures below are per ADR unless flagged “/ord.” “Core” is GSK’s own non-GAAP measure; “Total” is IFRS as reported. GBP→USD taken at ~$1.30/£.

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. The analysis that follows (sections 1–15) takes no position, names no price target, and carries no buy/sell recommendation; this section is the single exception.

Verdict: HOLD / own-for-the-value-and-yield / accumulate-on-weakness. Not a short. Conviction: medium. GSK is the cheapest quality name in large-cap pharma — and cheap for two real reasons, not one imagined one. At $53.66 it trades at ~14.5x trailing reported EPS but only ~11–12x forward Core EPS (~$4.5/ADR) — a clear discount to AstraZeneca/Novartis (~14–17x) and a premium only to the deepest cliff-value names (Merck/Pfizer/Bristol ~8–11x). My fair-value zone is ~$50–63 (≈11–14x forward Core EPS of ~$4.5–4.8, the band a low-20s%-ROIC, ~3% yielder with a managed cliff deserves); I would accumulate more aggressively toward the high-$40s (~10–11x Core), where the HIV cliff and vaccine-policy risk are more than paid for. At today’s price GSK is fair-to-slightly-cheap, not a bargain — the self-help recovery is in, the durability past the cliff is not settled.

The framing — grounded in the tape — is a low-vol defensive value-pharma that has already re-rated on self-help, not a falling knife and not a momentum chase. GSK is a beta-~0.3, zero-momentum-loading, zero-value-loading defensive (factor-model analysis) that ran ~+50% off its 2025 low to an all-time high of $60.14 (Feb-2026) as the ~$2.2bn Zantac litigation overhang cleared and the pipeline de-risked, then gave back ~11%. What the market has now priced is unmistakable: GSK’s price-to-sales sits at the 98th percentile of its own ten-year history — its richest-ever top-line multiple — even as its Core P/E stays sub-12x. That split is the whole thesis in one datum: the recovery is paid for; the post-cliff durability is doubted. What the market is under-crediting (the variant) is GSK’s demonstrated ability to replace a cliff — it out-grew the Advair collapse by building HIV and Specialty — and the mix-shift toward higher-multiple Specialty Medicines (~41% of sales today, guided >50% by 2031). What keeps this a HOLD, not a BUY: the offsets are genuinely unproven. A ~£7.7bn HIV franchise (~24% of group sales) hits loss-of-exclusivity from ~2028, with nothing individually large enough to replace it; ~28% of sales sit in vaccines exposed to a hostile US ACIP/RFK-Jr policy regime that already halved Arexvy; the moat is a full ~10 margin-points below AZN’s (72% vs 82% gross margin); and the new CEO’s first headline act is a $10.6bn, 40%-premium, all-cash Nuvalent acquisition — expensive, late M&A that dilutes Core EPS through 2028 and admits the organic oncology pipeline is thin.

What would flip me bullish: hard evidence the Specialty engine is out-running the cliff — long-acting HIV (cabotegravir) + depemokimab + Blenrep + Nuvalent oncology visibly net-adding while Core margin expands, Specialty crossing >50% of mix, and GSK tracking toward ≥£40bn for 2031. What would flip me bearish: the dolutegravir cliff proving un-replaceable (2027–28 Core EPS growth slips below mid-single-digit or guidance is cut), Shingrix US demand structurally rolling over on vaccine policy, or Nuvalent/serial-M&A destroying capital as leverage climbs.

Tag: “The cheapest quality in pharma — because the recovery is priced and the cliff isn’t solved.”

📈 Stock Price Action — Five-Year Event Map

Built from a five-year price history (split- and dividend-adjusted series) cross-referenced to GSK earnings dates, 6-K material events and the news feed. Price moves are FACT; attributed drivers are INTERPRETATION. No price target, no recommendation. Two structural events distort the raw screen price and are handled by the adjusted series: the Haleon consumer-health demerger (in-specie distribution, 18-Jul-2022), which reset GSK’s share base, and the continuous dividend stream — so the split-adjusted line (used throughout) sits below the unadjusted screen price in the early years (Sep-2021 low reads ~$20 adjusted vs ~$30 unadjusted).

The five-year arc, in plain numbers. On an adjusted basis GSK ran almost a full round-trip and then broke out: a demerger-era trough of ~$20 (28-Sep-2021), a choppy four-year base in the ~$26–40 band through 2022–2024 punctuated by the Zantac litigation panic, a sharp 2025 re-rating off ~$32, and a 2026 melt-up to an all-time high of $60.14 (18-Feb-2026), followed by a pullback to $53.66 (2-Jul-2026) — ~10.8% off the high, in the upper third of a $34.89–$60.14 trailing-52-week range.

Cycle narrative. (1) GSK bottomed near ~$20 in 2021 as the market punished the Haleon-demerger overhang, an activist campaign, and its absence from the COVID-vaccine race — the archetypal cheap-value pharma. (2) It rose ~+60% off that low into mid-2022 as the “new GSK” BioPharma story gained clarity and HIV/Shingrix compounded. (3) A sharp ~−20% Zantac litigation shock in Aug–Oct 2022 as US ranitidine claims triggered a tail-risk repricing. (4) A two-year grind back to ~$40 as the litigation tail de-escalated and earnings beat. (5) A ~−21% Q4-2024 fade on US vaccine-policy fear (RFK-Jr/ACIP), the Arexvy RSV setback, and the ~$2.2bn Zantac settlement. (6) A ~+50% 2025 re-rating once Zantac was effectively behind the company, the pipeline de-risked, and buybacks began. (7) A ~+25% melt-up to the $60.14 ATH on the 4-Feb-2026 FY-print (Core EPS +12%, 2031 outlook raised to >£40bn, enhanced capital returns) plus a defensive-rotation bid. (8) A ~11% orderly fade off the high on profit-taking and a market that greeted the $10.6bn all-cash Nuvalent acquisition as a rich, late admission that the organic pipeline is short — a pullback, not a break.

1. Executive Summary

GSK plc is a UK-domiciled global biopharmaceutical company — a pure-play biopharma since the July-2022 demerger of Haleon (consumer health) — that has quietly turned itself from an activist target into a self-help earnings-recovery story. FY2025 turnover was £32,667m (+4% reported / ~+7% CER) at a 72.4% gross margin and a 29.9% Core operating margin, generating £8.9bn of operating cash flow, ~£4.0bn of GSK-defined free cash flow, and a low-20s% ROIC that comfortably clears its ~8% cost of capital. It carries an investment-grade balance sheet (net debt £14.5bn, ~1.5x EBITDA, Moody’s A2 / S&P A), pays a ~3% dividend, and — new since 2024 — buys back stock. The stock has re-rated ~+50% off its 2025 low as the ~$2.2bn Zantac litigation overhang cleared, reaching an all-time high of $60.14 (Feb-2026) before easing to $53.66.

The investment question is not quality in the abstract — a low-20s% ROIC and a genuine no-biosimilar vaccine monopoly are real — but durability versus a discounted price. GSK is structurally different from its diversified peers in two ways that define the thesis. First, it is over-indexed to HIV (ViiV, ~£7.7bn, ~24% of sales), whose anchor molecule dolutegravir loses US exclusivity from ~April 2028 — a single-franchise cliff larger in concentration than anything AstraZeneca or Merck faces, which GSK is racing to re-base onto long-acting injectables (Cabenuva/Apretude) before generics arrive. Second, it is over-indexed to vaccines (~28% of sales vs low-single-digits at peers), which are impregnable to biosimilars but newly exposed to a hostile US vaccine-policy regime (HHS Secretary RFK Jr.'s ACIP overhaul), a demand-side risk that already halved Arexvy in 2024 and now shadows the ~£3.6bn Shingrix franchise. Layered on top are the sector-wide US pricing pressures (the IRA has already cut Trelegy’s US price ~73% effective 2027; MFN and tariffs loom), a moat a full ~10 gross-margin points below AZN’s (72% vs 82%, the cost of the vaccine/general-medicines mix), and a $10.6bn all-cash, 40%-premium Nuvalent acquisition (June-2026) — GSK’s biggest deal in over a decade — that plugs a sub-scale oncology franchise but dilutes Core EPS through 2028 and consumes balance-sheet headroom.

Against this, the bull ledger is real but unproven: a Specialty Medicines engine growing +17% (HIV, oncology +43%, respiratory/immunology +18%) guided to exceed 50% of sales by 2031; a differentiated launch pipeline (depemokimab’s twice-yearly anti-IL-5, the relaunched Blenrep, Nucala-COPD, Jemperli); a >£40bn-by-2031 sales ambition; and a demonstrated track record of replacing a prior cliff (Advair). On valuation, GSK trades at ~11–12x forward Core EPS — the cheap half of large-cap pharma, and at its richest-ever price-to-sales multiple (98th percentile of its own history) yet a still-modest earnings multiple. The tension in that split is the entire debate: the market has paid for the recovery but not for the durability past the cliff. This memo takes no position; the analysis that follows argues each verdict from the evidence.

2. Business Overview

What it does. GSK plc is a UK-domiciled global biopharmaceutical company — a pure-play “biopharma” since the July 2022 demerger of Haleon spun out the consumer-health business (Sensodyne, Advil, Panadol, Centrum). Post-demerger GSK discovers, develops, manufactures and commercialises patent-protected prescription medicines and vaccines across ~66,841 employees (Dec-2025) and ~75 markets. It is unusual within big pharma for the weight of its vaccines franchise — vaccines are ~28% of turnover versus a low-single-digit share at most peers (AstraZeneca’s vaccines are ~1.5% of product sales) — which is the single most important structural fact about GSK and the source of both its most durable moat and its most acute idiosyncratic risk (the relevant section/the relevant section). [Fact]

FY2025 scale. Turnover was £32,667m, +4% reported (AER) / +7% at constant currency (CER), with core operating margin 29.9% (+0.7pp), core EPS 172.0p (+8% AER / +12% CER), operating cash flow £8.9bn (+14%), gross margin 72.4%, and R&D of £7,525m (~23% of sales) — the highest R&D intensity in GSK’s post-demerger history and rising. [Fact — GSK FY2025 results, 4-Feb-2026]

Reporting structure. GSK reports two operating segments — Commercial Operations and Total R&D — but manages and discloses the business by three commercial franchises, which is the analytically useful cut:

[Fact — GSK FY2025 results]

Franchise detail.

• VACCINES (£9.2bn, +2%). The crown jewel is Shingrix (recombinant zoster, AS01-adjuvanted) at £3.6bn (+8%) — the world’s dominant shingles vaccine. Meningitis £1.6bn (+12%) (Bexsero, Menveo, and the new pentavalent Penmenvy approved 2025). Arexvy (RSV, older adults) recovered modestly to £0.6bn (+2%) — but only after a >50% collapse in FY2024 on an ACIP age-restriction . Plus Boostrix (pertussis) and a seasonal-flu book under competitive pricing pressure. The franchise was near-flat in 2025 as US Shingrix and Arexvy declined against IRA Part-D and policy headwinds. [Fact]

• SPECIALTY MEDICINES (£13.5bn, +17%) — three sub-franchises:

  • HIV (£7.7bn, +11%) via ViiV Healthcare. Ownership changed materially on 1-Apr-2026: GSK now holds 78.3%, Shionogi 21.7%, and Pfizer has fully EXITED (the old GSK-78% / Pfizer / Shionogi structure is stale). The dolutegravir franchise (~£5.7bn) anchors it: Dovato £2,678m (+22%), plus Tivicay/Triumeq (Triumeq declining) and Juluca; the long-acting injectables Cabenuva £1.4bn (+42%) and Apretude (PrEP) are the growth vector. [Fact]
  • Oncology (~£2.0bn, +43%) — GSK’s smallest-but-fastest franchise: Jemperli (dostarlimab) £861m (+89%), Ojjaara/Omjjara (momelotinib) £554m (+60%), Zejula (PARP, declining), and the Blenrep relaunch (belantamab mafodotin) — FDA re-approved 23-Oct-2025 in relapsed/refractory multiple myeloma on DREAMM-7/-8 after its 2022 withdrawal (£17m in 2025, a ramp not a level). [Fact]
  • Respiratory, Immunology & Inflammation (£3.8bn, +18%) — Nucala (mepolizumab) £2,008m (+15%), boosted by a US COPD approval (May-2025); Benlysta (lupus) £1,773m (+22%), ~82% US biologic-naïve share; and the newly approved ultra-long-acting IL-5 depemokimab (Exdensur), FDA-cleared for severe asthma 16-Dec-2025 (twice-yearly dosing — a differentiated convenience play). [Fact]

• GENERAL MEDICINES (£10.0bn, −1%) — the mature, lower-growth book: Trelegy (closed-triple COPD/asthma inhaler) >£2bn US / £3.0bn global (+13%) is the standout and the one IRA-negotiated product; plus Anoro, Augmentin/antibiotics, and established respiratory. Structurally the drag on group growth. [Fact]

Geography. GSK is majority-US-revenue: US turnover was £16,384m in FY2024 (~52% of the £31.4bn total) and remains ~half-plus in 2025, ahead of International (~£8.3bn) and Europe (~£6.7bn). [Fact — FY2024 regional split; FY2025 US % to confirm in the 20-F] This US weighting matters twice over: it is where the pricing/policy pressure concentrates (IRA, MFN, tariffs) and where the vaccine-policy risk bites hardest — an outsized exposure relative to the vaccine mix.

Business model. Like all research pharma, GSK is a portfolio of decaying patent annuities continuously replenished by R&D — each molecule earns 70–90% incremental margins behind a patent/regulatory wall until loss-of-exclusivity (LOE) collapses the price. GSK’s twist is the vaccine layer: vaccines carry longer de facto exclusivity (manufacturing complexity and adjuvant IP deter biosimilars far more than small-molecule generics) but lower gross margins and — uniquely — recommendation risk (a vaccine’s market can be legislated away by a committee vote, as RSV demonstrated). Revenue is recurring-but-finite per product; durability is a property of the pipeline-and-manufacturing machine, never of any single drug. [Interpretation]

Verdict. A genuine, diversified, post-Haleon biopharma pure-play whose growth engine (Specialty, +17%) is real and offsetting a flat vaccine book and a declining general-medicines tail. The quality of the book is good; the quality of the forward thesis hinges on two concentrated bets — the durability of Shingrix/vaccines against a hostile US policy backdrop, and ViiV’s ability to convert the dolutegravir franchise to long-acting injectables ahead of a 2028–29 patent cliff.

3. Industry Dynamics

Structure & profit pools. Global innovative biopharma is a structurally attractive, high-return, but politically besieged oligopoly — ~15 large-caps (LLY, NVO, JNJ, MRK, ABBV, AZN, PFE, NVS, Roche, BMY, AMGN, Sanofi, GSK, GILD, plus VRTX/REGN) command the innovative-drug profit pool at 70–85% gross margins. In Greenwald’s taxonomy the dominant barrier to entry is intangible assets in their purest legal form — patents plus regulatory data exclusivity granting a ~10–13-year government-sanctioned monopoly per asset — reinforced by economies of scale in R&D (only affordable at scale) and the FDA/EMA/MHRA acting as gatekeeper. It is one of the best industry structures in the market on a returns basis. [Interpretation, grounded in peer gross margins]

Where GSK sits — and why vaccines change the calculus. GSK is a mid-tier large-cap (~£33bn revenue vs AZN’s ~$59bn, Merck’s ~$64bn, Pfizer’s ~$60bn+) that is over-indexed to two sub-markets — vaccines (~28%) and HIV (~24%) — and under-indexed to oncology (~6% vs AZN/Merck at 40%+). That mix drives its industry exposure:

• Vaccines are structurally more defensible than small molecules on the supply side — the AS01 adjuvant, antigen manufacturing, and cold-chain scale are genuine barriers that keep Shingrix a near-monopoly with no biosimilar in sight — but structurally less defensible on the demand side in the current US regime, because a vaccine’s addressable market is set by a recommendation, not just a prescription. This is the single most important industry fact for GSK.
• HIV is a specialist, high-barrier, guideline-driven oligopoly (essentially ViiV vs Gilead) with strong pricing and adherence stickiness — attractive, but with a hard patent cliff approaching .
• Oncology is the most attractive sub-market (premium pricing, biomarker-segmented monopolies, physician-administered stickiness) — but GSK is sub-scale here versus AZN/Merck/BMS/Roche, which is precisely why it is paying $10.6bn for Nuvalent (Jun-2026) to buy oncology depth. [Interpretation]

The US drug-pricing regime — the sector-wide overhang. Three live US pressures hit GSK, weighted by its ~52% US exposure:

1. IRA Medicare negotiation + Part-D redesign. The Part-D redesign alone cost GSK ~£400–500m in FY2025 across Specialty, Vaccines and General Medicines; Trelegy has been through IRA price negotiation (a 2027 Maximum Fair Price of ~$175 vs ~$654 list, −73%; sister-product Breo −83%); future selection lists threaten more of the book as products cross the post-launch window. [Fact — GSK FY2025 results; CMS Nov-2025]
2. “Most Favored Nation” (MFN) pricing — a 2025 Executive Order pushing US prices toward the lowest developed-nation price, a structural threat to the US premium that funds global R&D. Peers (Pfizer, AstraZeneca) have signed MFN framework deals in exchange for tariff reprieves; GSK’s negotiating posture is a live open question. [Fact/Open Question]
3. Section-232 pharma tariffs — tiered tariffs (up to 100%) on imported drugs/APIs threatened from mid-2026; GSK’s US manufacturing footprint and a ≥$30bn US R&D+manufacturing pledge (Oct-2025) are the hedges. [Fact]

The GSK-specific overlay: vaccine-policy / RFK Jr. risk. This is the risk that separates GSK from every diversified-pharma peer, and it is material and escalating:

• HHS Secretary RFK Jr. overhauled ACIP — dismissed all 17 members and installed a smaller panel with vaccine-skeptical members; the CDC’s revamped childhood schedule was cut from 17 to 11 recommended vaccines (dropping/narrowing flu, rotavirus, hepatitis A/B, some meningitis, and RSV), and the panel lifted the 30-year universal newborn hepatitis-B recommendation. [Fact — CNN 9-Apr-2026; NBC/PBS 2025–26]
• A federal judge ruled the ACIP overhaul unlawful, postponing a meeting and invalidating the hep-B and COVID downgrade votes — so the policy is being fought in court, adding uncertainty on top of the direction of travel. [Fact]
• The RSV precedent is the template for the risk. In June 2024 ACIP narrowed the RSV recommendation from “all adults 60+” to “75+ and 60–74 at increased risk,” which cut Arexvy sales >50% in FY2024 and led forecasters to slash the projected 2030 RSV market ~64% (from ~$4.6bn to ~$1.7bn). GSK holds ~69% RSV share — so it absorbed the largest absolute hit. [Fact — CDC MMWR 2024; BioPharma Dive] A recommendation vote, not a competitor or a patent, halved a franchise. That is the mechanism to fear for Shingrix, meningitis and flu.

Marathon capital-cycle lens. Capital floods toward hot modalities (GLP-1/obesity, ADCs, radioligands, long-acting HIV) and away from cold ones; the patent system extends the high-return window per-asset but the modality-level cycle still bites. The read for GSK: it is not chasing the over-capitalised obesity pool (a rational abstention), it is incumbent in two under-crowded durable pools (adult vaccines, HIV) where capital is not flooding in — a Marathon-positive on the supply side — but the vaccine pool’s returns are being compressed by policy, not by capital, which the capital cycle does not price. [Interpretation]

Verdict: structurally GOOD industry, but GSK sits in the corner of it with a deteriorating demand-side overhang the peer group doesn’t share. The patent barrier + 70–85% gross margins + scale economics make innovative biopharma one of the best structures in the market. But GSK’s ~28% vaccine weighting exposes it to a US demand-side risk (recommendation withdrawal / hesitancy) that is idiosyncratic, escalating, and only partly in its control — layered on the same IRA/MFN/tariff pricing de-rating hitting the whole sector, amplified by GSK’s ~52% US mix. A good industry; a franchise mix that has gotten structurally worse at the margin in the places GSK is most concentrated (vaccines), and where GSK is best-positioned (oncology) it is sub-scale.

4. Competitive Position / Moat

Name the moat. GSK’s moat is intangible assets (patents + regulatory data exclusivity + prescriber/brand credibility) layered on genuine economies of scale in two specific places: vaccine adjuvant/antigen manufacturing and ViiV’s HIV specialist franchise. Switching costs are weak at the prescriber level (guideline-driven, not lock-in); network effects are nil. The honest characterisation is a “productivity + manufacturing” moat — durable in vaccines/HIV, thin in oncology, and everywhere finite-by-law per asset. [Interpretation]

The two genuine structural edges:

1. Vaccine manufacturing scale (Greenwald economies-of-scale + intangibles). This is GSK’s best and most durable moat. Shingrix’s AS01 adjuvant system and recombinant-antigen manufacturing are genuinely hard to replicate — there is no biosimilar Shingrix and none on the horizon, which is why GSK holds a near-monopoly in shingles and ~69% of the RSV market. Vaccine manufacturing is a scale-and-know-how barrier that behaves more like an industrial moat than a patent annuity: it does not collapse the day a patent expires. The caveat is that this moat protects against competitors, not against policy — and policy (ACIP/RFK) is exactly where the vaccine threat now comes from. A moat impregnable to biosimilars but vulnerable to a committee vote. [Interpretation, high-conviction]

2. ViiV HIV specialist scale. ViiV is a dedicated HIV company (GSK 78.3%) with the #1 integrase-inhibitor franchise (dolutegravir) and the first-mover long-acting injectables (Cabenuva treatment, Apretude PrEP). Deep guideline entrenchment, specialist salesforce, and adherence stickiness make this a real oligopoly moat (essentially ViiV vs Gilead). But it has the clearest expiry date of any GSK moat: dolutegravir’s US composition-of-matter patent expires ~April 2028 (+6-month pediatric), with a crystal-form patent to Dec-2029 and EU protection to ~mid-2029. A ~£5–6bn franchise faces a hard cliff at decade’s end — the single largest quantifiable threat to the moat. The entire ViiV strategy (converting oral dolutegravir patients to long-acting Cabenuva/Apretude, which carry fresh IP) is a race to re-base the franchise on injectables before the oral cliff hits. [Fact on patents; Interpretation on strategy]

Does the moat show up in the financials? (Greenwald ROIC test.)

*2024 depressed by the Zantac litigation provision + impairments. [Fact — company filings]

FY2025 ROIC ~22% comfortably clears a ~7–8% pharma WACC — the moat passes the Greenwald test with a wide, positive spread. But two tells matter:

• Gross margin (72%) is a full ~10 points below AstraZeneca’s (~82%), Merck’s (~82%) and Lilly’s (~83%). That gap is structural: vaccine manufacturing is capital- and COGS-intensive (adjuvant, antigen, fill-finish, cold chain) versus a small-molecule or antibody, and the ~31%-of-sales General Medicines book is a low-margin mature drag. GSK’s moat is real but lower-margin than an oncology/orphan-weighted peer — the vaccine mix that gives it durability also caps its margin ceiling. [Fact/Interpretation]
• ROIC is high but concentrated. The ~22% return is disproportionately earned by Shingrix + HIV — the two franchises facing, respectively, the vaccine-policy overhang and the 2028–29 dolutegravir cliff. High headline returns resting on two at-risk pillars is a quality-of-moat concern, not just a growth one. [Interpretation]

Market-share-stability test (the real moat evidence). Winning: Shingrix (near-monopoly, defended by manufacturing), HIV long-acting (Cabenuva +42%, Apretude — genuine share gains and category creation), Nucala/Benlysta (Benlysta ~82% US biologic-naïve lupus share), Jemperli/Ojjaara (small but taking share). Eroding/defending: RSV Arexvy (share high but the market was cut by ACIP), oral dolutegravir (Triumeq declining pre-cliff), Zejula (declining), flu (competitive pricing pressure). Mixed-positive: the specialty book is broadening (good for durability) but the two biggest profit pools are on defence.

Direct competitive standing, franchise by franchise:

The HIV competitive threat deserves emphasis. Gilead’s lenacapavir — Yeztugo (twice-yearly PrEP, FDA-approved Jun-2025) and a once-weekly oral in development — is a genuine dosing-convenience leap over ViiV’s every-2-month Apretude, arriving right as the dolutegravir cliff approaches. ViiV and Gilead settled their Biktarvy/dolutegravir patent litigation in Jan-2022 (Gilead paid royalties), so the near-term IP fight is resolved — but the product competition intensifies exactly when GSK can least afford share loss. This is the central bear pillar on GSK’s second-largest franchise. [Fact]

Oncology — the acknowledged gap. GSK’s ~£2bn oncology franchise (+43%) is growing fast off a small base but is sub-scale versus every major oncology peer; it lacks a mega-blockbuster anchor (no Keytruda/Enhertu/Tagrisso equivalent), and the Blenrep relaunch (re-approved Oct-2025 after a 2022 withdrawal) is a comeback story, not yet a proven annuity. The $10.6bn all-cash Nuvalent acquisition (Jun-2026) — precision oncology (ROS1/ALK) — is management’s explicit admission that oncology depth must be bought because it hasn’t been built. This is the anti-moat in the portfolio: the fastest-growing franchise is the one where GSK has the least durable advantage. [Fact/Interpretation]

Verdict: a durable but lower-margin and more concentrated moat than the diversified-pharma peer average. It passes the tests (ROIC ~22% >> WACC, 72% gross margins, a genuine no-biosimilar vaccine monopoly, HIV share gains in long-acting). It is unambiguously a good business. But the moat is (a) capped in margin by the vaccine/general-medicines mix (72% vs peers’ 82%), (b) concentrated in two franchises each facing a specific, dated threat — Shingrix/vaccines against US recommendation-and-hesitancy policy, and HIV against a 2028–29 dolutegravir cliff plus Gilead’s lenacapavir — and © thin exactly where the industry is most attractive (oncology), forcing a $10.6bn acquisition to compensate. Better than a no-moat commodity or a one-drug cliff name; narrower and more policy-exposed than AstraZeneca’s oncology-led moat. The thesis reduces to two empirical bets: does the vaccine franchise survive the RFK/ACIP regime, and does ViiV re-base to long-acting injectables before the 2028–29 cliff?

5. Growth History and Forward Opportunities

The historical record — a demerger-reset company that quietly compounded. Turnover: £24.4bn (2020) → £24.7bn (2021) → £29.3bn (2022) → £30.3bn (2023) → £31.4bn (2024) → £32.7bn (2025) — a ~6% five-year CAGR on the reported line, but the number understates the underlying pharma engine because 2020–2021 still carried the consumer-health business spun as Haleon in July 2022. [Fact] Post-demerger “New GSK” is a biopharma pure-play, and on that clean base the growth has accelerated: FY2025 was +4% AER / +7% CER, with the mix tilting decisively toward the higher-quality end. [Fact]

Decomposition by franchise — Specialty is doing the work; Vaccines and General Medicines are flat-to-soft. FY2025 (FACT, GSK FY2025 results):

The signal is unambiguous: Specialty Medicines (+17%) is the entire growth story, General Medicines is a declining legacy base (−1%), and Vaccines — once GSK’s crown-jewel differentiator versus AstraZeneca — has stalled at +2% and is the most policy-fragile franchise in the company. [Interpretation] Growth is overwhelmingly organic (volume + new launches), with bolt-on M&A (Boston Pharmaceuticals for efimosfermin, 2025) supplementing rather than carrying the base — a cleaner organic story than AZN’s Alexion-inflated line, but off a smaller, cliff-exposed franchise.

The forward ambition — “>£40bn by 2031,” and the escalating-target tell. GSK’s long-term guidance has been serially upgraded: the original June-2021 “New GSK” plan targeted “>£33bn sales by 2031” with “adjusted operating margin >30% by 2026” [Fact, GSK 2021 investor update]; this was raised and, at the FY2025 print (04-Feb-2026) and the 3-June-2026 investor update (“Bets on Specialty Medicines to Drive Long-Term Revenue Growth”), reaffirmed at “>£40bn by 2031” [Fact; Zacks/Reuters, 03-Jun-2026]. From the £32.7bn 2025 base, >£40bn implies a ~4% CER CAGR — modest in absolute terms but demanding given that a ~£7.7bn HIV franchise faces loss-of-exclusivity mid-window . Management’s framing: Specialty rises from >40% of sales today to >50% by 2031 (guided “low double-digit CER” in 2026; Q1-2026 Specialty +14% to £3.2bn), explicitly designed to out-grow the HIV cliff and the soft Vaccines/General Medicines base. [Fact/Interpretation] The escalating target is a double-edged tell: it signals genuine pipeline confidence, but a company that keeps raising a 2031 number is also anchoring expectations that a single HIV-cliff or vaccine-policy miss could puncture. [Interpretation]

The forward catalyst stack (bull ledger). GSK names its five-year “principal growth drivers” [Fact, 03-Jun-2026]:

• Depemokimab (Exdensur) — ultra-long-acting anti-IL-5, 2x/year dosing, the highest-conviction pipeline asset. FDA-approved for severe eosinophilic asthma (Dec-2025, SWIFT-1/2); UK-approved in asthma + CRSwNP; EU CHMP-positive; Japan-approved. The twice-yearly dosing is a genuine convenience moat vs Dupixent/monthly biologics across asthma/COPD/CRSwNP/EGPA — potential blockbuster. [Fact/Interpretation]
• Blenrep (belantamab mafodotin) — returned to the US market October 2025, but on a split FDA decision: the DREAMM-7 BVd combo approved (≥2 prior lines, vs the 1 GSK requested) while the DREAMM-8 BPd combo was rejected over ocular-toxicity (92% of patients; Grade 3/4 in 77%) and dosing-optimisation concerns. [Fact — STAT/BioPharma Dive, 23-Oct-2025] A real relaunch, but narrower and later than the bull case.
• Camlipixant (P2X3, refractory chronic cough, Phase 3), efimosfermin (FGF21, MASH — via the 2025 Boston Pharmaceuticals deal), Nucala/mepolizumab COPD expansion, bepirovirsen (hepatitis B, Phase 3), Jemperli (endometrial/colorectal), Ojjaara/momelotinib (myelofibrosis; orphan VEXAS designation 12-Jun-2026), and next-gen HIV long-acting (2028–2030). [Fact]
• Nuvalent oncology (announced 09-Jun-2026, $10.6bn — see the relevant section): zidesamtinib (ROS1, PDUFA 18-Sep-2026) and neladalkib (ALK, PDUFA 27-Nov-2026) — two potential best-in-class NSCLC inhibitors bought at late stage to deepen the thin (£2.0bn) oncology franchise. [Fact]

Verdict: MEDIUM-to-HIGH quality growth — real, organic, Specialty-led volume, but structurally hostage to a single-franchise cliff and a policy-fragile vaccine book. The composition is improving (Specialty +17%, oncology +43%, a genuine convenience-differentiated launch in depemokimab), and unlike a melting single-drug name GSK has breadth. But the growth is lower-quality than AZN’s on two counts: (1) it must first replace a ~£7.7bn HIV franchise losing exclusivity in 2028–2030 before the £40bn/2031 target is even net-additive, and (2) Vaccines — the historic differentiator — has gone ex-growth (+2%) and sits in the crosshairs of US vaccine policy. The £40bn ambition is a stretch that leans on flawless Specialty execution plus M&A (Nuvalent, Boston Pharma) to bridge the gap.

6. Financial Quality

Multi-year trends (IFRS “Total” unless noted; GBP).

*The 2024 IFRS figure is depressed by the Zantac settlement and impairments (bridge below); it is not a run-rate. Net income attributable (£5,716m FY2025) reconciles cleanly. †2022 net income is distorted by the +£10.7bn Haleon demerger gain in discontinued operations — disregard it as an earnings signal.

Revenue and mix. Turnover compounded a pedestrian ~6.0%/yr 2020→2025, but the quality of that revenue improved markedly. The single most important financial fact is the ~500bp gross-margin expansion, from 67.4% (2020) to 72.4% (2025), driven by mix-shift toward higher-margin Specialty Medicines and away from lower-margin Established/General medicines. This is a business getting structurally more profitable per pound of sales — the first test of “do economics improve with scale,” and it passes. [Fact/Interpretation]

The GAAP→Core reconciliation — the central QoE issue. Like AstraZeneca, GSK’s guided and market-followed metric is Core (adjusted) EPS, and the gap to IFRS “Total” is large. FY2025: Core operating profit £9,783m vs Total £7,932m — an £1,851m bridge — and Core EPS 172.0p vs Total 141.1p (a ~22% gap). The FY2025 add-backs (£m): intangible amortisation £808 + intangible impairment £880 + major restructuring £109 + transaction-related £507 + legal/divestments/other (453) = 1,851. Two observations. First, unlike AZN (whose gap is ~90% clean amortisation of one acquired franchise), GSK’s bridge is lumpier and more impairment-heavy: the £880m of intangible impairment in a single year is a write-down of pipeline/product assets that failed to deliver — a recurring cost of the bolt-on model, not a one-off. Second, FY2024 is the cautionary tale: the Total→Core bridge that year was £5,127m — Core £9,148m vs Total only £4,021m — dominated by transaction-related £1,881m and legal/other £1,577m, overwhelmingly the Zantac litigation settlement (~$2.2bn), plus £314m impairment. IFRS Total EPS collapsed to 63.2p while Core held at 159.3p. Interpretation: the Core-vs-Total gap is not merely bookkeeping amortisation — in GSK’s case it also absorbs genuine, cash-costly legal settlements and repeated impairments. Core is the right lens for operating momentum, but it flatters the through-cycle truth more than AZN’s does.

Cash corroboration. The reassurance is that the gap is mostly non-cash and cash-backed: cash generated from operations was £8,943m (2025), giving OCF/net-income (attrib.) of 1.56x — operating cash exceeds reported earnings by roughly the magnitude of the non-cash charges. But note GSK’s own-defined free cash flow of £4,029m (2025) sits below a naïve CFO-minus-capex figure (~£4.76bn). The ~£0.7bn wedge is the tell: GSK’s FCF definition deducts distributions to non-controlling interests — the ViiV preferential dividends paid to the JV minorities — plus net interest/tax. This is a real cash leakage to minorities that headline Core EPS does not fully surface, and it makes GSK’s conservative £4.0bn the shareholder-relevant number. [Fact/Interpretation]

The ViiV contingent-consideration overhang. FY2025 carried a £649m charge on the Shionogi ViiV contingent consideration (£404m discount unwind + £245m remeasurement), partly offset by a £93m credit on the Pfizer put-option/preferential-dividend revaluation. These non-operating, mark-to-model swings on the ViiV JV structure are a recurring source of IFRS noise. They are being simplified: in Jan/Apr-2026 Pfizer’s economic interest was replaced by Shionogi (up to 21.7%; GSK retained 78.3%), and the Pfizer put-option liability was extinguished through retained earnings — removing one moving part but confirming how much of the reported result is JV-structure accounting rather than operations. [Fact]

R&D intensity — rising, productivity unproven. Total R&D reached £7,525m (FY2025, ~23% of sales), up from ~20% in 2020; on a Core basis R&D was £6,568m (~20.1%). The gap between the two (~£1bn) is itself impaired/amortised R&D intangibles and restructuring stripped out of Core — i.e., a portion of the “R&D” spend is being written off. Rising R&D intensity is only good capital allocation if it earns a return; GSK’s ROIC (below) says it is adequate, not exceptional, and the recurring impairments are the flip-side. SG&A runs ~£7–7.3bn (~22% of sales). SBC is low and clean at ~£307–374m/yr (~1% of sales) — no dilution game. [Fact]

Returns. ROIC rose from 9.2% (2020) to 21.9% (2025), with the 2024 dip to ~15% reflecting the Zantac-depressed profit. Even discounting the aggregation, a low-20s% ROIC comfortably clears an ~8% WACC. ROE (~55% in 2025) is a thin-equity artifact — buybacks and the negative-tangible-book structure inflate it — and should be disregarded. Tangible book value is negative: intangibles of £23,766m (goodwill £7,018m + other £16,748m) exceed the £16,377m of attributable equity, so tangible book is roughly −£3.9/ADR. For an IP-and-brand business this is acquisition accounting, not distress — but it is a reminder that the balance sheet carries a large stock of acquired intangibles that must earn out or be impaired (and £880m was impaired in 2025 alone). [Fact/Interpretation]

Balance sheet. Net debt was £14,453m (FY2025, GSK basis incl. leases), up from £13,095m in 2024 (~£13.7bn ex-leases per ROIC), for net debt/adjusted-EBITDA of ~1.5x — comfortably deleveraged from ~2.4x at the 2022 Haleon demerger. Interest cover is ~12x. Ratings are solidly investment-grade: Moody’s A2 (stable) and S&P A (stable, affirmed 22-May-2025) — a notch below AZN’s A1/A+ but strong. The pension is a modest £1.7bn liability. Liquidity is adequate (current ratio ~0.82, normal for the sector). This balance sheet has meaningful debt capacity — which management is about to spend . [Fact]

Verdict: ABOVE-average financial quality for large pharma, but a step below AZN — and not pristine. In its favour: 72% and rising gross margins, ~30% Core operating margin, ROIC in the low-20s% well above WACC, 1.56x cash conversion, ~1.5x leverage, A2/A ratings, negligible SBC/dilution. The caveats are real and specific: (1) the Core-vs-Total gap is impairment- and litigation-heavy, not just clean amortisation — GSK’s adjustments flatter the through-cycle picture more than a pure-amortisation add-back would; (2) the ViiV minority leakage means headline Core EPS overstates cash accruing to GSK shareholders, which is why GSK’s own £4.0bn FCF is the honest number; and (3) recurring intangible impairments (£880m in 2025) are the running cost of the bolt-on model. Economics do improve with scale — but modestly, and R&D re-absorbs most of the operating leverage by design.

7. Capital Allocation

The framework post-Haleon. Since spinning out Haleon in July 2022, GSK has run a pure-play biopharma capital model with four claims on cash, in rough priority: (1) R&D (~£6.6bn Core / ~£7.5bn total, the largest single use); (2) bolt-on M&A to refill the pipeline; (3) a progressive dividend; and (4), new since 2024, a buyback. The tell in the FY2025 numbers: dividends paid £2,564m + buyback £1,362m = £3,926m of shareholder returns against £4,029m of GSK-defined free cash flow — i.e., GSK is now distributing ~100% of its own free cash flow, leaving deleveraging and M&A to be debt-funded. That is the context for the Nuvalent deal. [Fact/Interpretation]

Nuvalent — the defining bet, and a return to big-ticket M&A. On 9-Jun-2026 GSK agreed to acquire Nuvalent for $10.6bn all-cash ($124/share, a ~40% premium; net-of-cash ~$9.4bn), its largest deal in over a decade; the tender offer commenced 24-Jun-2026 with an expected ~Q3-2026 close, funded from new and existing debt facilities plus cash (and it assumes Nuvalent’s low-single-digit royalty obligations to Royalty Pharma/Deerfield). The assets are two late-stage, highly selective kinase inhibitors — zidesamtinib (ROS1) and neladalkib (ALK) for non-small-cell lung cancer — both under FDA review with Breakthrough/Orphan designations and potential 2026 approvals. Strategic read (Interpretation): coherent with GSK’s stated strategy of buying validated-target assets that improve on standard-of-care tolerability, and it plugs GSK’s thinnest franchise (oncology) with near-commercial, best-in-class-candidate molecules — the “buy late, buy de-risked” logic that reads well. But the price is full: a ~40% premium and ~$10.6bn of cash for two not-yet-approved drugs. As guided: low-single-digit Core EPS dilution through 2028, revenue/operating-profit contribution from 2027, and Core EPS accretion from 2029 — so shareholders wait ~3 years for payback. It pushes net debt/EBITDA from ~1.5x toward ~2x+ (net debt heading to ~£22–24bn), using up the headroom the A2/A ratings afforded. Strategically defensible but not cheap; the verdict rides on the two FDA decisions and the launch trajectories.

The bolt-on program — disciplined, mixed results. Pre-Nuvalent, GSK ran a steady string of sub-$2.5bn, modality- and pipeline-acquiring deals: Sierra Oncology (~$1.9bn, 2022, momelotinib/Ojjaara), Affinivax (~$2.1bn, 2022), Bellus Health (~$2.0bn, 2023, camlipixant), Aiolos Bio (2024, ~$1bn up-front + milestones, asthma), Boston Pharmaceuticals/efimosfermin (2024, hepatology), plus smaller assets. Interpretation: the strategy is coherent (respiratory/immunology and specialty focus, risk-shared structures), and the individual cheques are small relative to ~£4bn FCF. But the £880m of intangible impairment in 2025 and repeated pipeline setbacks show the hit-rate is imperfect — this is a portfolio bet where some assets are already being written down. Disciplined in sizing, uneven in outcome.

Dividend — progressive off a reset base. GSK cut the dividend at the 2022 Haleon demerger (from ~80p pre-demerger to a 61.25p rebased 2022 payout — the consumer cash flows went with Haleon), then resumed progression: 58p (2023) → 60p (2024) → 64p (2025), paid £2,564m in 2025 and covered ~1.57x by GSK-defined FCF. Per ADR (2 ordinary) that is ~128p ≈ ~$1.6, a ~3.0% yield at the $53.66 ADR. The policy is sustainable but unspectacular; the dividend cut is a permanent scar on GSK’s “aristocrat” reputation that the market has not forgotten. [Fact/Interpretation]

Buyback — new, and now competing with M&A for the same cash. GSK launched its first buyback in years in 2024 (a £2bn programme) and executed £1,362m in 2025. Interpretation: rational at a ~13x Core P/E, but the timing is awkward — GSK is buying back stock and funding a $10.6bn cash acquisition with debt in the same 12 months, which is effectively levering up to buy back shares. With FCF already ~100% distributed, the buyback is debt-financed at the margin; defensible only if the shares are genuinely cheap and the leverage temporary.

Executive incentives — the ROIC gap, again. The 2025 PSP/LTIP vests on: Relative TSR 40%, Total sales + Core operating-profit growth 35%, Pipeline Sustainability 17.5%, Responsible Business scorecard 7.5% (3-year performance + 2-year holding). The critical gap (Interpretation): like AZN, there is no explicit ROIC/return-on-capital metric — and notably the Adjusted Free Cash Flow measure that carried 30% weight in the 2020–22 plans appears to have been folded into the sales/operating-profit-growth line. For a company that has just committed $10.6bn of debt-funded cash to an acquisition, rewarding sales and operating-profit growth (both buyable with M&A) and TSR (market-driven) — while dropping an explicit cash-return/return-on-capital governor — is the wrong incentive design at the wrong moment. This is GSK’s single most important capital-allocation governance weakness, mitigated only by mandatory shareholding requirements.

Management transition & pay. Luke Miels became CEO on 1-Jan-2026 (previously Chief Commercial Officer since 2017); Emma Walmsley (CEO 2017–2025) left the Board on 31-Dec-2025 with a notice period to 30-Sep-2026. Walmsley’s FY2025 single-figure pay was £15.6–15.7m (up ~50% from £10.6m in 2024) — LTIP £10m + bonus £3.5m — inflated by a vesting share price that rose to £21.65; the ~50% jump in a departure year, off a plan lacking a return-on-capital metric, is a poor look. Miels inherits the strategy (specialty-led growth, the Nuvalent integration, the looming HIV cliff) rather than resetting it. Insider signalling is low-value here: as a UK issuer GSK director dealings are RNS “PDMR” notices (routine vestings/sell-to-cover), not the discretionary open-market conviction buys a US Form 4 corpus would show. [Fact]

Verdict: adequate-to-good, disciplined capital allocation — now being tested by a large, full-priced, debt-funded acquisition and undermined by an incentive plan with no return-on-capital governor. In GSK’s favour: a coherent specialty-focused pipeline strategy, small risk-shared bolt-ons, a covered (if previously cut) progressive dividend, a rational new buyback, and conservative leverage entering the Nuvalent deal. Against it: (1) Nuvalent is a ~40%-premium, ~$10.6bn cash bet that dilutes Core EPS through 2028 and consumes balance-sheet headroom; (2) GSK is distributing ~100% of FCF and buying back stock while debt-funding M&A — levering up at the margin; (3) recurring intangible impairments signal an imperfect M&A hit-rate; and (4) the LTIP still rewards buyable sales/profit growth and TSR with no explicit ROIC metric. Whether this capital allocation proves intelligent hinges almost entirely on two 2026 FDA decisions.

8. Changes and Headwinds — Last Two Years

1. LEADERSHIP: CEO succession — CONFIRMED. After eight years, Emma Walmsley (CEO since 2017) stepped down; Luke Miels — Chief Commercial Officer since 2017 — became CEO and joined the board on 1 January 2026 [Fact — GSK press release, Sep-2025; SEC 6-K]. Walmsley left the board 31-Dec-2025 and remains through her notice period to 30-Sep-2026 for an orderly handover. Interpretation: an internal, commercial-DNA appointment — Miels ran the drug/vaccine P&L and is closely associated with the Specialty pivot, so strategy continuity is high; the risk is that a commercial (not scientific or capital-allocation) CEO inherits a company whose central problem is R&D productivity and cliff-replacement, and whose first headline act (Nuvalent) is a large, full-priced deal.

2. Nuvalent — a $10.6bn oncology bet, GSK’s biggest in over a decade. Announced 9-June-2026: an all-cash tender at $124/share (~$10.6bn / £8.0bn equity; ~$9.4bn net of cash), a 40% premium (26% to 30-day VWAP), for two late-stage NSCLC assets — zidesamtinib (ROS1, PDUFA 18-Sep-2026) and neladalkib (ALK, PDUFA 27-Nov-2026), both Breakthrough + Orphan designated [Fact; SC TO-T commenced ~24-Jun-2026]. Guided accretive to sales and core operating profit in 2027, core EPS in 2029. Interpretation: strategically coherent (deepens a sub-scale £2.0bn oncology book with validated-target, best-in-class candidates) but expensive and pre-revenue — a 40% premium for two not-yet-approved drugs, funded onto a balance sheet already at ~1.5x net-debt/EBITDA (rising), and a bet the new CEO owns from day one.

3. HIV patent cliff — the single largest revenue risk, clock now audible. Dolutegravir — the ~£7.7bn ViiV franchise (Dovato/Triumeq/Juluca) — loses core exclusivity: US composition patent April 2028, EU July 2029, Dovato formulation Dec-2029, Juluca July-2030 [Fact — drugpatentwatch/FiercePharma; GSK: “three quarters of it is 2029”]. This is a bigger concentration risk than any single AZN drug — one franchise is ~24% of group sales. GSK’s offset: pivot the foundation from dolutegravir to cabotegravir long-acting (Cabenuva/Apretude) and an ultra-long-acting (4-month+ dosing) treatment/PrEP pipeline extending patents into the 2030s [Fact]. Interpretation: credible but unproven — long-acting injectables must convert a large oral base fast enough to outrun generics, and the 2028–2030 window overlaps precisely with the £40bn/2031 ambition.

4. Zantac litigation — mostly, but not fully, behind. October-2024 GSK settled ~93% of state-court cases (~80,000 claims) for up to $2.2bn, implemented by H1-2025; a $70m qui tam (Valisure) agreed in principle [Fact — pharmaphorum; GSK statement]. The federal MDL (~2,233 cases, Oct-2025) was dismissed on Daubert (science) grounds — a favourable outcome — but plaintiffs are appealing [Fact — Drugwatch]. No admission of liability. Interpretation: the tail is now small and largely provisioned (the £2.2bn drove the depressed 2024 reported operating margin); a materially reduced overhang versus 2023–24, not a fully-closed one.

5. US vaccine policy — the defining new structural headwind; ~£9.2bn (~28% of sales) exposed. HHS Secretary RFK Jr. dismissed the entire ACIP panel in June 2025, replacing it with vaccine skeptics — injecting durable uncertainty into the CDC recommendation process that drives US vaccine demand [Fact — FiercePharma/CIDRAP]. GSK is the most vaccine-exposed large-cap in the cohort. Concrete damage is already visible in Arexvy, whose sales collapsed 51% (£1.2bn 2023 → £0.59bn 2024) after the 2024 ACIP narrowed the RSV recommendation; ACIP has since re-expanded (50–59 at-risk) and the FDA extended Arexvy to 18–49 at-risk (H1-2026), a partial recovery [Fact]. Interpretation: the Arexvy round-trip is the template for the tail risk — an unfavourable ACIP vote can vaporise a vaccine franchise regardless of the underlying science, and Shingrix (£3.6bn, US already declining) is the far larger asset now exposed to the same politicised process.

6. IRA drug-price negotiation — Trelegy hit for 2027. Trelegy Ellipta was selected in the second IRA cycle: a 2027 Maximum Fair Price of $175 vs $654 list (−73%), with sister-product Breo at −83% [Fact — BioPharma Dive/CMS, Nov-2025]. Trelegy (£3.0bn, +13% in 2025) is GSK’s largest General Medicines asset — the cut bites one of the few growing pieces of an otherwise flat segment, from 1-Jan-2027.

7. Tariffs & the US manufacturing pledge. Against the administration’s threatened 100% tariff on branded pharma imports (announced 25-Sep-2025), GSK pledged ≥$30bn of US R&D + manufacturing over five years, including a ~$1.2bn Pennsylvania biologics factory [Fact — GSK release; CNN/BioPharma Dive]. Interpretation: part strategic (GSK sells heavily into the US), part political insurance — like AZN’s $50B pledge, it hedges tariff/MFN risk at the cost of future capex/FCF, with uncertain incremental IRR.

8. Pipeline/regulatory tape — genuinely mixed in 2025–26. Wins: depemokimab (Exdensur) US asthma approval; Utebzi (Spero oral carbapenem, FDA 17-Jun-2026); momelotinib VEXAS orphan designation. Setbacks: the Blenrep split decision (DREAMM-8 rejected, DREAMM-7 restricted to ≥2 lines; the relevant section) and the ongoing Vaccines softness [Fact]. Not uniformly bullish.

Verdict: NET NEUTRAL-to-MILDLY-WEAKENING near-term, with genuine forward optionality layered on top. The last two years removed one overhang (Zantac largely settled) and added two structural ones that AZN does not carry: the US vaccine-policy regime (~28% of sales exposed, already demonstrated on Arexvy) and the IRA Trelegy cut. Sitting behind both is the 2028–2030 HIV cliff — the single fact that most constrains the £40bn/2031 ambition. Against these, the offsets are real but unproven: a strategy-continuity CEO, the large Nuvalent oncology bet, and depemokimab’s differentiated launch. The tape is not a clean strengthening story — it is a company deliberately spending (Nuvalent, US capex) and re-pricing its pipeline to outrun a cliff and a hostile US policy backdrop, and whether that works is the central 2026–2031 question.

9. Risk Analysis

Catastrophic-loss risk: LOW. GSK is diversified across three franchises and ~75 markets, ~£32.7bn revenue, IG balance sheet (A2/A, ~1.5x leverage pre-Nuvalent), ~£8.9bn OCF. No single-event wipeout; the realistic bear is the HIV cliff out-running the pipeline + vaccine-policy impairment → a multi-year growth stall and de-rating toward the cliff-value names, not insolvency. Total-loss probability: negligible.

10. Valuation Discussion

Where GSK trades (2-Jul-2026: $53.66/ADR; ~2.006bn ADRs → market cap ~$108bn / ~£83bn; EV ~£88bn pre-Nuvalent, net debt ~£13.7bn). Reconcile the ADR carefully — 1 ADR = 2 ordinary shares, so every per-share figure below is stated per ADR.

• Reported (total IFRS) EPS ~$3.71/ADR → P/E ~14.5x. The headline screen multiple.
• Core EPS 172.0p ordinary (+12% in FY2025) ≈ 344p/ADR ≈ ~$4.5/ADR → trailing Core P/E ~12x. On 2026 guidance of +7–9% Core EPS growth at CER (≈ ~$4.8/ADR), the forward Core P/E is ~11–12x — the multiple the market and sell-side actually underwrite.
• Own-history valuation percentiles are the key tell: P/E 65.6th, P/B 48.9th, and P/S 98.3rd — the richest-ever on sales (composite 71st). Read together, this is a stock whose sales multiple has never been higher while its earnings multiple is only mid-range — i.e., the market has re-rated the top line on the strength of the recovery/self-help story, not (yet) fully on earnings. EV/EBITDA ~10.5x, EV/Sales ~2.7x, P/FCF ~7x. Dividend ~$1.6/ADR (~3.0% yield) plus a ~£2bn buyback (new since 2024) lifts total shareholder yield toward ~5%.

Peer cross-read (approx. forward earnings basis).

GSK sits squarely in the cheap half of large-cap pharma — a clear discount to the growth names (AZN/NVS/Roche ~13–17x) and to Sanofi, but a premium to the deepest cliff-discount value names (MRK/PFE/BMY ~8–11x). The multiple is the market’s verdict on GSK’s central tension: a real self-help earnings recovery and rising Specialty mix, discounted for the 2028+ HIV/dolutegravir patent cliff and a structural US vaccine-policy overhang (Shingrix/Arexvy/US ACIP) that its faster-growing peers do not carry to the same degree.

Embedded expectations (reverse-DCF intuition). GSK guides to >£40bn sales by 2031 (raised from >£38bn) — from £32.7bn in 2025, only ~3–4% revenue CAGR — plus Core operating-margin expansion and 7–9% Core EPS growth (buyback-aided). At ~11–12x forward Core the market is not paying for that guided algorithm. Backing into the multiple, the price appears to underwrite roughly: low-single-digit sales CAGR (~2–3%), Core EPS growth decelerating toward mid-single-digits post-2027 as the ~£6–7bn HIV/dolutegravir franchise rolls off, and Core margin holding but not materially expanding. In plain terms, the market is underwriting the dolutegravir cliff being only partially offset by Specialty/pipeline — a growth stall, not the guided >£40bn. The richest-ever P/S says the recovery is priced; the sub-12x Core P/E says the durability past the cliff is doubted. The upside case is not that GSK is a hidden compounder — it is that the market is over-discounting a franchise that has already replaced one cliff (Advair) and is bending its mix toward higher-multiple Specialty.

Scenarios (illustrative, Core EPS/ADR × exit multiple; no price target).

• Bear: dolutegravir cliff out-runs the pipeline; Specialty scales but vaccines and General Medicines shrink; 2031 sales stall ~£34–36bn; Core EPS/ADR flat-to-~$4.5; multiple de-rates to ~9–10x (toward Merck/Pfizer).
• Base: guidance roughly met — 2031 sales ~£40bn, Specialty >50% of mix, Core margin expands modestly; Core EPS/ADR compounds ~6–8% to ~$5.5–6.0 by 2028–29; multiple holds ~11–13x.
• Bull: depemokimab + Blenrep + Nuvalent oncology + long-acting HIV out-run the cliff; 2031 sales >£42bn; Core margin expands toward high-30s%; Core EPS/ADR ~$6.5+; multiple re-rates toward ~14–15x on proven durability.

What the market is pricing correctly: the HIV/dolutegravir cliff is real and large; the US vaccine-policy overhang is structural; and Nuvalent is expensive, late M&A. What it may be pricing incorrectly (the variant): GSK’s demonstrated ability to replace cliffs (Advair → HIV/Specialty), the higher-multiple Specialty mix shift (>50% by 2031), and a self-help margin/earnings recovery the sub-12x multiple gives little credit. (No price target — embedded-expectations and scenarios only.)

11. Variant Perception

Consensus belief. “A low-growth, structurally-challenged UK value-pharma — Zantac litigation now behind it and executing a genuine self-help earnings recovery — but facing a heavy 2028+ HIV/dolutegravir patent cliff and a US vaccine-policy overhang (Shingrix/Arexvy/ACIP), so it deserves a cheap-half multiple (~11–12x forward Core), well below AZN/Novartis and only a notch above the deepest cliff-discount names. The >£40bn 2031 target is aspirational; model a stall.” The tape shows the divergence sharply: GSK has re-rated ~+50% off its 2025 low to an all-time high and its P/S is at the 98th percentile of its own history, yet its forward Core P/E is still ~11–12x — the market has bid the recovery while refusing to pay for durability past the cliff.

Factor positioning (the empirical read). Factor-model analysis classifies GSK as a low-volatility, defensive Health-Care large-cap: beta ~0.3–0.5, a very strong BetaFactor loading of −0.77 to −0.89 (the low-beta/defensive signature), Health-Care sector +0.48 to +0.54, Quality +0.17 to +0.26, a UK-country +0.29, and a bond-proxy InterestRate −0.25 to −0.31. Critically, Momentum ~0.00 and Value ~0.00 — despite the +43% twelve-month relative strength (rs_12m +42.9%), the model reads GSK as neither a momentum name nor a value name. Alpha is positive (+0.14) and r² is only 0.27–0.43, so >half its variance is its own drug/policy story. The classification is unambiguous: a low-vol quality/defensive that has already RE-RATED — NOT a falling knife (a knife shreds 30–50%; GSK is up), NOT deep value (zero Value loading, richest-ever P/S), and NOT a crowded momentum blow-off (zero Momentum loading; the move was fundamentally driven by Zantac relief + earnings recovery). The honest read is a crowded defensive bid meeting a real self-help recovery — a bond-proxy that caught a flight-to-quality plus rotation into cheap defensives, now giving ~11% back off the ATH. That is the evidence base for the “quality-recovery, already partly paid for” framing.

Strongest bull case. GSK is the cheapest quality large-cap pharma at ~11–12x forward Core with a ~5% total shareholder yield. Its Specialty engine (HIV, oncology, respiratory/I&I) grew +14% in Q1-2026 and is targeted to be >50% of revenue by 2031, structurally lifting the mix toward higher-multiple, patent-protected franchises. Depemokimab (ultra-long-acting anti-IL-5), the returned/relaunched Blenrep, Jemperli, long-acting injectable HIV (cabotegravir/Apretude), and now Nuvalent’s precision-oncology assets give real shots at out-running the dolutegravir cliff — exactly as GSK previously replaced the Advair cliff. The vaccine-policy fear is arguably overdone: Shingrix demand is demographic and global, and Arexvy’s collapse is largely already in the base. If GSK merely tracks its own guidance, the sub-12x multiple is too cheap.

Strongest bear case. The 2028+ dolutegravir cliff hits a ~£6–7bn HIV franchise (ViiV) with nothing individually large enough to replace it, and long-acting HIV cannibalises as much as it adds. The US vaccine-policy shift is structural, not cyclical — an ACIP/RFK-Jr regime that has already gutted Arexvy and threatens Shingrix/US vaccine access, permanently impairing ~a fifth of the book. Nuvalent at $10.6bn all-cash (40% premium) is expensive, late M&A that tacitly admits the organic pipeline is short and pushes net debt/EBITDA up from ~1.5x. Growth has stalled before (2024 operating income was depressed by the Zantac provision and impairments), and at a richest-ever P/S with rising R&D intensity (~23% of sales), the market has already paid for the recovery — leaving GSK a value-trap risk if 2031 lands nearer £35bn than £40bn.

The 3–5 assumptions that matter most. (1) HIV cliff replacement — do long-acting HIV + Specialty net-add enough to offset the 2028+ dolutegravir roll-off? (2) Vaccine policy — is the US ACIP/RFK-Jr overhang a cyclical air-pocket (Arexvy already based) or a structural impairment of Shingrix/US vaccines? (3) Specialty mix shift — does Specialty actually reach >50% of sales (re-rating the multiple) or stall? (4) Nuvalent/M&A discipline — value-creating pipeline top-up or a serial-bolt-on capital drag? (5) >£40bn 2031 credibility — does GSK narrow toward the target (re-rate) or settle in a ~£35–37bn stall (de-rate)?

Falsification tests. Bull falsified if: 2027–28 Core EPS growth slips below mid-single-digit or guidance is cut; Shingrix US demand structurally rolls over on policy; a major Specialty/pipeline Phase-3 setback (depemokimab/Blenrep); or Nuvalent underdelivers. Bear falsified if: Specialty crosses toward >50% of mix while long-acting HIV + oncology visibly offset the dolutegravir cliff, Core margin expands, and GSK tracks toward ≥£40bn for 2031 — re-rating the multiple toward Novartis/Sanofi.

Net. GSK is neither a falling knife nor a momentum blow-off — it is a low-vol defensive value-pharma that has already re-rated on Zantac relief and a real self-help recovery, but whose sub-12x Core multiple still prices a growth stall past the HIV cliff. The variant is that the market is paying up on sales (richest-ever P/S) while under-crediting GSK’s proven cliff-replacement track record and the mix shift into higher-multiple Specialty — so the debate is durability, not quality, and the next 8–12 quarters of HIV-replacement and vaccine-policy data will settle it.

12. Fact vs. Interpretation Table

13. Open Questions

1. How fast does long-acting HIV convert the oral dolutegravir base? ViiV must re-base a ~£6–7bn franchise onto Cabenuva/Apretude (and 4-month+ next-gen) before the ~2028 US generic wave — the single most important number for the whole thesis. GSK promised more HIV-pipeline detail at Q2-2026 results.
2. Is the US vaccine-policy overhang cyclical or structural for Shingrix? Arexvy showed the mechanism; the question is whether ACIP/RFK actions (or hesitancy) durably impair the ~£3.6bn Shingrix franchise or merely dent US growth for a year or two.
3. Which further GSK products land on future IRA negotiation lists after Trelegy — Nucala, Benlysta, Ojjaara and the HIV franchise are all plausible, a recurring quantifiable margin headwind.
4. Do zidesamtinib and neladalkib both clear FDA in 2026 (PDUFAs 18-Sep and 27-Nov), and at what launch trajectory — the Nuvalent deal’s entire IRR rides on these two decisions.
5. Does GSK sign an MFN/tariff framework like Pfizer/AZN, and on what terms — its posture on US pricing is a live open question.
6. Will the 2031 “>£40bn” target be reaffirmed or quietly trimmed as the HIV-cliff window arrives — the escalating-target history cuts both ways.
7. Depemokimab’s real-world uptake — does twice-yearly dosing convert enough of the biologic asthma/COPD market to become the blockbuster the bull case needs, against entrenched Dupixent?
8. Does the Zantac MDL appeal reopen the tail, or is the litigation genuinely closed?

14. What Must Be True

For the BULL case (GSK out-runs the cliff and re-rates toward the growth-pharma cohort):

• Specialty Medicines must scale through the HIV cliff: long-acting HIV (cabotegravir), depemokimab, Blenrep, Jemperli and Nuvalent oncology must net-add enough to offset the 2028+ dolutegravir roll-off, with Specialty crossing >50% of revenue and GSK tracking toward ≥£40bn 2031 sales and 7–9% Core EPS growth.
• The US vaccine-policy overhang must prove cyclical, not structural — Shingrix demand holds globally and Arexvy is already based, so vaccines stabilise rather than structurally decline.
• Core operating margin must expand (not just hold) as the mix shifts to Specialty, and Nuvalent must earn its cost of capital.
• Falsification test: 2027–28 Core EPS growth slips below mid-single-digit, or Specialty growth decelerates below double-digit, or Shingrix US demand structurally rolls over, or a depemokimab/Blenrep Phase-3 setback lands. Any one materially breaks the bull.

For the BEAR case (GSK de-rates toward the cliff-value names):

• The dolutegravir cliff must out-run the pipeline: the ~£6–7bn HIV franchise erodes from 2028 faster than long-acting HIV + Specialty can replace, and 2031 sales stall toward ~£34–36bn.
• US vaccine policy must prove structural — ACIP/RFK-Jr regime permanently impairs Shingrix/US vaccine access (~a fifth of the book).
• M&A must destroy value — Nuvalent and further bolt-ons drag returns while net debt rises, and the richest-ever P/S de-rates toward ~9–10x Core (Merck/Pfizer).
• Falsification test: Specialty crosses >50% of mix while long-acting HIV + oncology visibly offset the dolutegravir cliff, Core margin expands, and GSK tracks ≥£40bn for 2031. That outcome breaks the bear.

The two cases turn on one empirical question the next 8–12 quarters will answer: does GSK’s Specialty engine replace the dolutegravir cliff the way it once replaced Advair — with the vaccine franchise intact?

Embedded-expectations summary (what ~11–12x forward Core is pricing).

(No price target anywhere; embedded-expectations and scenario framing only.)

15. Source Appendix

See GSK_source_appendix.md (Appendix B in the combined report) for the full source list. Primary sources: GSK plc FY2025 results announcement and results 6-K (04-Feb-2026), the Q1-2026 results 6-K and earnings call (29-Apr-2026), the 3-June-2026 investor update, the Nuvalent tender-offer documents (SC TO-T, 24-Jun-2026), the ViiV shareholding-change release (Jan-2026), and the 2025 GSK Annual Report / Remuneration Report. Quantitative data reconciled via public market-data sources. Qualitative/regulatory facts (IRA Trelegy price, ACIP/vaccine policy, Zantac resolution, FDA approvals/PDUFAs, patent-expiry dates, pipeline data) cross-referenced to CMS, CDC, FDA, and trade press (FiercePharma, Reuters, BioPharma Dive, STAT, pharmaphorum, drugpatentwatch), each cited inline with access date 2026-07-03.

APPENDIX A — Standard Diligence Questionnaire

GSK plc (NYSE: GSK) — supplemental to the research memo · 2026-07-03

Fact/Interpretation/Assumption labels applied where it matters. Greenwald (Competition Demystified) and Marathon (Capital Returns) frameworks applied where they add insight. Per-share figures per ADR (= 2 ordinary shares) unless “/ord.”

General

What thoughtful questions have other investors asked about this company? The recurring institutional debate is a single question with several faces: can the Specialty engine replace the HIV/dolutegravir cliff (2028+) before it hits, and can the vaccine franchise survive US policy? Sub-questions: (1) how fast do long-acting HIV injectables (Cabenuva/Apretude) convert the oral dolutegravir base? (2) Is the RFK/ACIP vaccine overhang cyclical or a permanent impairment of Shingrix? (3) Was Nuvalent ($10.6bn, 40% premium) a smart late top-up or an admission the pipeline is short? (4) Is the >£40bn-by-2031 target credible or serially over-promised? (5) Why does GSK trade at its richest-ever P/S yet only ~12x Core P/E — is the recovery already priced? [Interpretation]

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Neither cyclical — pharma earnings track the patent/launch cycle, not the macro cycle. GSK’s Core earnings are on a genuine recovery trajectory (Core EPS +12% CER FY2025, guided +7–9% for 2026), but that recovery precedes a franchise-specific cliff (dolutegravir 2028+). So earnings are “mid-cycle rising into a known step-down,” not high or low in a macro sense. [Interpretation] The 2024 reported (IFRS) trough was an artifact of the ~$2.2bn Zantac provision, not operations.

Driven by external environment or internal actions? Predominantly internal — the mix-shift to Specialty, new launches (depemokimab, Nucala-COPD, Blenrep), and buyback-aided EPS are self-help. The external overlays (IRA pricing, ACIP vaccine policy, FX) are headwinds, not tailwinds. [Interpretation]

How stable are revenues? Moderately stable but concentrated: ~24% of sales in HIV (facing a dated cliff) and ~28% in policy-exposed vaccines. More concentrated and less stable-looking through 2028–30 than a diversified peer like AZN or Novartis. [Fact/Interpretation]

Outlook for products/services; how big is the market? The addressable markets (HIV, adult vaccines, respiratory/immunology, oncology) are large and mostly growing, but GSK’s two biggest pools face specific pressures — HIV a patent cliff, vaccines a demand-side policy risk. Oncology (where the market is most attractive) is where GSK is sub-scale and buying in. Growing overall, but the quality of the growth is franchise-dependent. [Interpretation]

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More competitive on price (IRA/MFN/biosimilars) and, for GSK specifically, more hostile on vaccine demand (ACIP). HIV competition is intensifying (Gilead’s lenacapavir). [Fact/Interpretation]

How profitable is the business (ROIC, ROE)? ROIC ~21.9% (2025), well above an ~8% WACC — a genuine moat signal. ROE (~55%) is inflated by thin equity/buybacks and should be disregarded. Gross margin 72.4% (rising) but ~10pts below oncology-weighted peers. [Fact]

How profitable is the industry — competitors, barriers to entry? Innovative biopharma is one of the highest-return structures in the market (70–85% gross margins) behind patent + regulatory-data + scale barriers. ~15 large-cap competitors; barriers to entry are very high (a decade + billions to bring a drug through FDA). [Interpretation]

Can the business be easily understood? Reasonably — three franchises, a patent-annuity model. The complications are the ViiV JV minority structure and the Core-vs-Total (IFRS) reconciliation. [Interpretation]

Can it be undermined by foreign low-cost labour? No — the threat is generics/biosimilars (post-patent) and policy (price cuts), not labour arbitrage. Vaccine manufacturing scale is itself a barrier. [Interpretation]

Do brands matter? At the physician/payer level, clinical data and guideline inclusion matter more than consumer brand; Shingrix and the ViiV franchise have real prescriber-brand equity. (GSK’s consumer brands went to Haleon in 2022.) [Interpretation]

Nature of competition; customers’ switching costs? Competition is on efficacy, safety/tolerability, dosing convenience (depemokimab’s 2x/yr, long-acting HIV) and price. Switching costs are moderate — guideline-driven and stickier in vaccines (near-monopoly Shingrix) and HIV (adherence) than in general medicines. [Interpretation]

Financial Condition & Balance Sheet

Assets not fully recognised on the balance sheet? The pipeline and the vaccine-manufacturing know-how are internally generated and largely unrecognised. Conversely, a large stock of acquired intangibles (£23.8bn) is recognised and must earn out — £880m was impaired in 2025. [Fact]

Off-balance-sheet liabilities? ViiV contingent consideration / preferential dividends to minorities (a recurring cash and IFRS drag); operating commitments; the residual Zantac appeal tail; ~$30bn US manufacturing pledge (future capex). Pension is a modest £1.7bn on-balance-sheet liability. [Fact]

How conservative is the accounting? Mixed. Core (adjusted) EPS strips out genuine, cash-costly items (litigation, impairments) more aggressively than a pure-amortisation add-back — so Core flatters the through-cycle truth. GSK’s own FCF definition (deducting minority distributions) is, by contrast, conservative and the right shareholder number. [Interpretation]

How CapEx-hungry is the business? Moderately — capex + intangibles ~£3bn/yr (~9% of sales); vaccine manufacturing is more capital-intensive than a pure small-molecule peer, and the US pledge adds future capex. [Fact]

Capital Allocation & Management

How much FCF, and how is it used? ~£4.0bn GSK-defined FCF (2025); ~100% now distributed via dividend (£2.56bn) + buyback (£1.36bn), leaving M&A (Nuvalent) debt-funded. Philosophy: R&D first, then bolt-on M&A, then progressive dividend, then buyback. [Fact]

Significant acquisitions recently? Yes — Nuvalent ($10.6bn all-cash, 40% premium, Jun-2026), the biggest in over a decade, plus a string of ~$1–2bn bolt-ons (Sierra, Affinivax, Bellus, Aiolos, Boston Pharmaceuticals). [Fact]

Buying back shares? Yes — a £2bn programme begun 2024; £1.36bn executed in 2025. Rational at ~13x Core but debt-financed at the margin given ~100% FCF payout + the Nuvalent cash outlay. [Fact/Interpretation]

Issuing large amounts of new shares to insiders? No — SBC is low (~£350m/yr, ~1% of sales); share count is declining via buyback. Clean. [Fact]

Compensation policy / incentive alignment? 2025 PSP: Relative TSR 40% + Total sales & Core operating-profit growth 35% + Pipeline 17.5% + Responsible Business 7.5%. No explicit ROIC/return-on-capital metric — the key governance weakness, sharpened by the debt-funded Nuvalent bet. Walmsley’s FY2025 pay rose ~50% to ~£15.7m in a departure year. [Fact/Interpretation]

Motivations of management? New CEO Luke Miels (from 1-Jan-2026), a commercial-DNA internal appointee, is incentivised on TSR + sales/profit growth (both M&A-buyable) — alignment is adequate but imperfect absent a capital-return governor. [Interpretation]

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? An ADR (1 ADS = 2 ordinary shares); UK plc, IFRS/GBP reporter, files 20-F/6-K. Not an MLP; no K-1. US holders should note UK dividend mechanics and potential ADR fees. [Fact]

Dividend policy? Progressive off the 2022 demerger-rebased base: 58p → 60p → 64p/ord (2023→25); ~$1.6/ADR, ~3.0% yield, ~1.57x FCF-covered. [Fact]

How profitable is the business? Very — 72% gross, ~30% Core operating margin, ~22% ROIC. [Fact]

Is net income diverging from cash from operations? In the right direction — OCF (£8.9bn) exceeds reported net income (£5.7bn) at 1.56x, reflecting non-cash charges; a positive quality-of-earnings signal, tempered by the minority-leakage wedge in FCF. [Fact]

Risks & Downside

What factors would cause the stock to decline? (1) Evidence the dolutegravir cliff is un-replaceable (2027–28 Core EPS growth slips / guidance cut); (2) a structural vaccine-policy hit to Shingrix; (3) a Nuvalent/pipeline setback (Sep/Nov-2026 PDUFAs); (4) IRA/MFN deepening; (5) de-rating from the richest-ever P/S. [Interpretation]

Risk of a catastrophic loss? Low — diversified, IG-rated (A2/A), ~1.5x leverage, ~£8.9bn OCF. The realistic bear is a multi-year growth stall and de-rating, not impairment of the enterprise. [Interpretation]

Chance of a total loss? Negligible. [Interpretation]

Recent News & Events

Has the business environment changed recently? Materially, yes: (1) Nuvalent $10.6bn acquisition (Jun-2026); (2) CEO change — Miels from 1-Jan-2026; (3) ViiV restructured — Pfizer exited, GSK 78.3% / Shionogi 21.7% (Apr-2026); (4) Zantac largely settled (federal MDL dismissed, on appeal); (5) US vaccine policy (RFK/ACIP) hardened; (6) Trelegy IRA cut confirmed for 2027; (7) >£40bn/2031 target reaffirmed at the 3-Jun-2026 investor update; (8) multiple approvals (depemokimab, Utebzi, Blenrep-DREAMM-7). [Fact]

Significant acquisitions? Nuvalent (above), plus Boston Pharmaceuticals (efimosfermin) and prior bolt-ons. [Fact]

Change in accounting policies? None material flagged; the ViiV put-option extinguishment (through retained earnings) simplifies the JV accounting. [Fact]

Recent changes — new markets, facilities, management? New CEO; ~$30bn US R&D+manufacturing pledge including a ~$1.2bn Pennsylvania biologics site; Penmenvy and depemokimab launches. [Fact]

APPENDIX B — Source Appendix

GSK plc (NYSE: GSK) · Research date 2026-07-03

Primary before secondary; recent before stale. GSK is a UK foreign private issuer — SEC filings are 20-F/6-K/SC TO-T (CIK 0001131399), not 10-K/10-Q. All quantitative figures reconciled to GSK’s own IFRS results. Per-share figures per ADR (= 2 ordinary shares) unless “/ord.”

Primary filings & company disclosures (SEC EDGAR, CIK 0001131399; company IR)

• GSK plc FY2025 Results Announcement and results 6-K (04-Feb-2026) — turnover £32,667m, Core operating margin 29.9%, Core EPS 172.0p, franchise splits, >£40bn/2031 guidance, dividend 64p, buyback.
• GSK plc Q1-2026 Results 6-K and earnings call transcript (29-Apr-2026) — sales +5% CER to £7.6bn, Specialty +14%, Core operating profit +10%, EPS +9%, Q1 dividend 17p, dolutegravir-LoE / long-acting HIV commentary.
• GSK 3-June-2026 investor update (“Bets on Specialty Medicines to Drive Long-Term Revenue Growth”) — long-term growth drivers; Specialty >50% of sales by 2031.
• Nuvalent acquisition: GSK/Nuvalent joint press release (09-Jun-2026); SC TO-T / SC TO-T/A tender-offer documents (commenced 24-Jun-2026); $124/share, ~$10.6bn all-cash, 40% premium; zidesamtinib (ROS1) / neladalkib (ALK).
• ViiV shareholding change — GSK/Pfizer/Shionogi press release (Jan-2026): Pfizer exits, GSK 78.3% / Shionogi 21.7% (effective 1-Apr-2026).
• Luke Miels CEO appointment — GSK press release (Sep-2025; effective 1-Jan-2026); Emma Walmsley departure.
• GSK 2025 Annual Report / Remuneration Report & Policy — PSP/LTIP metrics (TSR 40% / sales+core-op-profit 35% / pipeline 17.5% / responsible business 7.5%); FY2025 executive single-figure pay.
• GSK 2021 “New GSK” investor update — original >£33bn/2031 and >30% margin ambitions (baseline for the escalating-target read).

Earnings-call transcripts (public financial databases)

• GSK Q1-2026 (29-Apr-2026), Q4-2025/FY25 (04-Feb-2026), and prior 2024–25 quarters — read for forward guidance, HIV-cliff framing, launch commentary.

Regulatory / policy / clinical (public)

• CMS — IRA Maximum Fair Price list (Trelegy ~$175 vs ~$654, −73%; Breo −83%), effective 2027; Part-D redesign.
• CDC / ACIP MMWR — 2024 RSV recommendation narrowing (Arexvy −51% FY2024); 2025–26 ACIP overhaul, childhood-schedule reduction, hepatitis-B newborn recommendation change; federal-court ruling on ACIP process.
• FDA — depemokimab (Exdensur) severe-asthma approval (16-Dec-2025); Blenrep DREAMM-7 approval / DREAMM-8 CRL (23-Oct-2025); Utebzi (Spero, oral carbapenem cUTI, 17-Jun-2026); Nucala COPD (May-2025); zidesamtinib/neladalkib PDUFAs (18-Sep / 27-Nov-2026); Gilead lenacapavir/Yeztugo PrEP (Jun-2025).
• drugpatentwatch / trade press — dolutegravir patent-expiry timeline (US ~Apr-2028; EU ~2029).
• Ratings — Moody’s A2 (stable); S&P A (stable, affirmed 22-May-2025).

Litigation

• Zantac — Oct-2024 ~$2.2bn state-court settlement (~93% / ~80,000 claims); Valisure $70m qui tam; federal MDL Daubert dismissal (Oct-2025) under appeal.

Trade press / secondary (cited inline, accessed 2026-07-03)

• FiercePharma, Reuters, BioPharma Dive, STAT, pharmaphorum, Drugwatch, CNN, CIDRAP, PharmExec, MarketScreener, Zacks/Yahoo Finance.

Frameworks

• Greenwald & Kahn, Competition Demystified (moat-type taxonomy, ROIC/share-stability tests); Marathon Asset Management, Capital Returns (supply-side capital-cycle lens).